ArticleClinical and translational medicine2025
Organoid-based two-step drug screening for rapid identification of chemotherapy-resistant oesophageal squamous cell carcinoma and alternative therapies.
Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Animal organoids as models for integrated One Health research.One health (Amsterdam, Netherlands) · 2026Review
- Deconstructing cancer in 3D: models, mechanisms, and personalized solutions.Molecular cancer · 2026Review
- Tumor organoid platform design for drug response modeling: culture architecture, microenvironmental complexity, and AI-assisted readouts.Archives of pharmacal research · 2026Review
- Organoid-based two-step drug screening for rapid identification of chemotherapy-resistant oesophageal squamous cell carcinoma and alternative therapies.Clinical and translational medicine · 2025Article
- Advances in esophageal organoids: from construction to applications.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDespite guideline-directed therapies, most patients with advanced oesophageal squamous cell carcinoma (ESCC) derive limited benefit and are unable to tolerate iterative treatment modifications. Therefore, timely identification of resistant cases and the provision of alternative therapeutic options are urgently needed.
methodsA large-scale patient-derived organoid model was established from locally advanced patients with ESCC who underwent perioperative chemotherapy and was validated for consistency with the parental tumours through histopathological, genomic and transcriptomic analysis. A novel two-step drug screening method based on growth rate inhibition (GR) was developed, and drug sensitivity results were compared with clinical outcomes. Additionally, in vivo assays were conducted to evaluate alternative therapies using the C
resultsESCC organoids demonstrated high consistency with parental tumours in histopathology, genomics and transcriptomics. The two-step drug screening method revealed a strong correlation with clinical responses (sensitivity 80%, specificity 85.7%, overall accuracy 83.3%) and significantly shortened the experimental timeline compared with the traditional drug screening method (23.08 ± 2.42 days vs. 45.75 ± 7.19 days, p < .001). Furthermore, we proposed a novel drug selection strategy based on C
conclusionsThis method exhibits strong clinical applicability, supporting more accurate and timely decision-making in ESCC management. The C
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.